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ABSTRACT 
Objective: The present research work aims to develop an abuse deterrent rapidly dissolving buprenorphine microemulsion loaded sublingual film 
for the treatment of breakthrough pain.  
Methods: The Buprenorphine microemulsion loaded sublingual films were prepared using Capmul MCM C8 (oil), tween 20 (surfactant) and 
propylene glycol (co-surfactant) with different grades of film-forming polymer (HPMC) using film casting machine. The films were evaluated for in 
vitro disintegration and dissolution study, tensile strength, folding endurance, content uniformity, surface pH, thickness and weight variation, % 
loading of buprenorphine microemulsion in sublingual film, scanning electron microscope, ex vivo permeation study, droplet size and polydispersity 
index, Zeta potential, % moisture content, stability and abuse deterrent potential were evaluated.  
Results: The optimized film formulation showed desired mechanical properties with minimum disintegration time of 21s and exhibited 34.45 % 
loading of Buprenorphine microemulsion. Permeation studies through goat sublingual mucosa, indicated 87% Buprenorphine release, through 
Buprenorphine microemulsion loaded sublingual film, whereas only 30% Buprenorphine release when it was directly added to film without 
microemulsion strategy.  
Conclusion: The present study concludes that abuse deterrent and fast acting buprenorphine microemulsion-incorporated sublingual film of 
buprenorphine HCL and naloxone HCL is a promising alternative to mostly marketed buprenorphine injectable delivery systems and a non-invasive 
route of administration for breakthrough pain management.  
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INTRODUCTION 
Buprenorphine hydrochloride (BU) is a partial agonist at mu (µ) and 
kappa (K) opioid receptor and antagonist at delta receptors used for the 
treatment of moderate to severe pain as well as chronic pain [1]. BU, 
being a tasteless drug and slightly acidic in nature, has two pKa values of 
8.42 and 8.92 and logP of 3.4. Hence, at pH<8.4, it can be well absorbed 
[2]. The low oral bioavailability of BU (31%) limits its therapeutic utility 
and it also undergoes extensive first pass metabolism by hepatic 
cytochrome P-450 3A4 isozyme. Hence oral formulations of BU are not 
available in the market whereas parenteral, buccal and sublingual 
formulations are available [3-5]. With respect to buccal formulations, 
buprenorphine’s buccal film Bunavail®is available in the market. This 
bilayered film increases the total bioavailability of BU to more than 40% 
in healthy subjects [6]. Bai et al., carried out the pharmacokinetic study 
of BU buccal film formulation in healthy volunteers and the study 
revealed that bioavailability of BU was about 46 to 51% [7]. This 
indicates further research in the enhancement of the BU is to be carried 
out for better bioavailability.  
Poor aqueous solubility of drug entities is today considered as a 
formidable challenge for pharmaceutical scientist, which is considered as 
an area of prime importance in the field of biomedical research. Hence 
lipid based formulations were chosen to overcome the above barriers 
and among them microemulsion (ME) as drug delivery systems have 
recently gained wide acceptance due to robust formulations 
perspectives, ease of production and practical enhancement of drug 
permeability [8]. The o/w microemulsion formulation enhances the 
sublingual and buccal bioavailability of lipophillic drug BU by facilitating 
transcellular (across the cell) and paracellular (between the cells) 
absorption. Thus literature review reveals lack of information about the 
bioavailability enhancement of poorly water soluble buprenorphine 
using microemulsion as drug delivery systems. 
Also, opioid analgesics are foremost used for the treatment of 
breakthrough pain in cancer. To fight the transient breakthrough pain, 
it is necessary to achieve quick drug release from dosage form for the 
early onset of action for the purpose of pain management. This can be 
achieved with the help of a sublingual or buccal delivery of 
buprenorphine. The added advantage of the geometrical shape and 
larger surface area of thin films can be utilized to deliver an active 
drug sublingually [9]. Based on extensive review of literature, it 
revealed that controlled delivery buccal patches of buprenorphine has 
been developed using polyisobutylene, polyisoprene and carbopol 
934P as bioadhesive polymer. Nearly 75% of the buprenorphine 
released after in vitro evaluation studies from the buccal patches 
following 24 h incubation period [10]. Also bilayed buccal film of BU is 
available with bioavailability of more than 40% in healthy subjects 
[11]. At the same time literature study also revealed that BU sublingual 
formulations are diverted and utilized outside of an established 
physician–patient relationship, both for self-medication of withdrawal 
symptoms and to produce euphoria [12, 13]. 
Thus, the current study was aimed to develop an abuse deterrent, 
fast dissolving microemulsion loaded sublingual film of 
buprenorphine for transient breakthrough pain. To achieve this 
objective, microemulsion is incorporated into the sublingual film for 
better sublingual bioavailability. But, since buprenorphine is having 
a high risk of abuse potential [14-16], naloxone is incorporated in a 
fixed ratio (1 mg of naloxone per 4 mg of buprenorphine) to deter 
abuse by parenteral route, such as nasal insufflations or injection. 
Naloxone hydrochloride (NA) has no therapeutic effect but still 
added to the formulation to prevent parental abuse. Because when 
patient tries to abuse this formulation parentally, naloxone binds to 
the receptor site in the brain and blocks the receptors, thus reducing 
the effect of BU and prevents the abuse potential of the formulation.  
MATERIALS AND METHODS  
Materials 
BU and NA was purchased from Sun Pharmaceutical Industries Ltd. 
Propylene Glycol was purchased from Shell Chemicals, Singapore. 
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Capmul® MCM C8 (Mono/diglycerides of caprylic acid) was obtained 
as a gift sample from ABITEC Corporation, Columbus, USA. Monebat®-
20 (Polyoxyethylene 20 sorbitan monolaurate) was obtained as a gift 
sample from Mohini Organics Pvt. Ltd. Malad (West), Mumbai. 
Methods 
Preparation of BU microemulsion loaded and NA sublingual films 
Polymeric ME drug loaded sublingual film was prepared using glass 
plate and further optimized bates were casted using film casting 
machine at 1.5 V and wet thickness of 0.50 mm and dimensions of 
film was set at 20 × 22.5 mm and dried immediately. Preparation of 
BU microemulsion and polymeric solutions used to make the films 
are as follows. Weigh each ingredient accurately as described in 
table 1 to prepare formulations F1 to F27. Initially, BU 
microemulsion was prepared using Capmul MCM C8 (oil), tween 20 
(surfactant) and propylene glycol (co-surfactant) using water 
titration method. In C2 optimized microemulsion Smix ratio was 1:1 
(table 1) and in A2 it was 2:1 (table 2) [17]. This resulted into 
formation of clear microemulsion and to it calculated quantity of BU 
was added and sonicated for 30 min. Then alpha tocopherol acetate 
and BHA (as an antioxidant), sucralose (sweetener), sunset yellow 
(color) and orange flavor were added and further sonicated for 20 
min to obtain solution A. Separately, HPMC E15, HPMC E50 was 
dissolved in water by continuous stirring and allowed to swell for 60 
min until a clear solution was obtained. NA was added to aqueous 
solution of polymers and mixed to obtain a homogeneous mixture to 
obtain solution B.  
Then, BU loaded ME i.e. solution A was mixed with hydrated 
polymeric solution i.e. solution B with continuous stirring on 
mechanical stirrer (Remi motors, Remi Electrotechnik Ltd., Vasai, 
Mumbai, India) for nearly 40 min to obtain a homogeneous mixture 
i.e. solution C. Finally, solution C was cast on the film casting 
machine and allowed to dry at 50 °C for 40 min. On removal from 
the release liner, the film was checked for any imperfections before 
being cut into 20 × 22.5 mm squares. Further Scale up trail bathes 
with increase in batch size was taken as shown in table 3. 
 
Table 1: Composition of BU microemulsion loaded sublingual films with Smix ratio of ME as 1:1 (optimized C2 ME) 
Ingredients (%) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 
Buprenorphine HCl - - - - - - - - - - 3.21 





14.65 13.09 11.37 10.87 10.73 8.19 6.83 6.67 6.88 6.62 6.20 
Tween-20 42.97 38.41 33.35 31.88 31.47 24.01 20.09 19.56 20.18 19.41 18.19 
PG 19.49 17.42 15.13 14.46 14.27 10.89 9.08 8.87 9.15 8.80 8.25 
H2O in ME q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. 
HPMC E5 16.96 15.16 13.17 12.58 - - - - - - - 
HPMC E15 5.08 15.16 13.17 17.00 31.11 47.43 52.99 54.08 63.79 65.17 63.24 
Xanthan gum 0.84 0.75 0.65 0.62 - - - - - - - 
PVA - - 6.58 6.29 6.21 9.48 11.07 10.82 - - - 
Glycerin - - 6.58 6.29 6.21 - - - - - - 
D. M. water q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. 
 
Table 2: Composition of BU microemulsion loaded sublingual films with Smix ratio of 2:1 (optimized A2 ME) 
Ingredients (%) F12 F13 F14 F15 
Buprenorphine HCl - - - 3.07 
Naloxone HCl - - - 0.87 
A2 ME 
Smix (1:1) 
Capmul MCM C8 7.39 7.55 7.27 6.83 
Tween-20 14.54 14.86 14.30 13.43 
PG 14.54 14.86 14.30 13.43 
H2O in ME q. s. q. s. q. s. q. s. 
HPMC E15 53.72 62.72 64.13 62.36 
PVA 10.74 - - - 
D. M. water q. s. q. s. q. s. q. s. 
 
Table 3: Composition of scale up batches of BU A2 ME loaded sublingual films on film casting machine 
Ingredients (%) F16 F17 F18 F19 F20 F21 F22 F23 F24 F25 F26 F27 
Buprenorphine HCl - - - - - - - - - - 3.93 3.93 





6.85 8 9.6 10.66 10.21 10.21 8.73 8.73 8.73 9.6 8.73 8.73 
Tween-20 13.48 15.73 18.88 20.97 20.08 20.08 17.16 17.16 17.16 18.88 17.16 17.16 
PG 13.48 15.73 18.88 20.97 20.08 20.08 17.16 17.16 17.16 18.88 17.16 17.16 
H2O in ME q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. 
HPMC E 15 61.44 55.01 46.02 40.02 42.57 25.53 41.82 41.82 41.82 30 28.07 24.44 
HPMC E 50 - - - - - 17.02 - - - 16 14.54 16.36 
Carbopol  
971 P 
- - - - - - 9.09 - - - - - 
Sodium CMC - - - - - - - 9.09 - - - - 
Polyox N80 - - - - - - - - 9.09 - - - 
Sucralose 1.43 1.66 2 2.22 2.12 2.12 1.81 1.81 1.81 2 1.81 1.81 
Orange flavor 0.71 0.83 1 1.11 1.06 1.06 0.90 0.90 0.90 1 0.91 0.91 
Sunset yellow color 0.01 0.01 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.02 0.01 0.01 
Alpha tocopherol 
acetate 
2.14 2.5 3 3.33 3.19 3.19 2.72 2.72 2.72 3 5.45 7.27 
D. M. water q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. 
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Characterization of BU microemulsion loaded and NA 
sublingual film 
In vitro disintegration study  
In vitro disintegration of film was performed as described. Initially, the 
film was carefully clamped from both the side and placed in a beaker 
in such a way that water level should be at half level of the film. The 
time required to break the film was recorded as disintegration time. 
Mechanical characterization 
Tensile strength 
The prepared films were subjected for the determination of 
mechanical properties using using LINUX Tensile Tester (model TEN 
MD), LINUX Machine Incorporation, Thane, Maharashtra, India, 
instrument according to the procedure described as follows [18]. 
The films of dimensions 30×5 mm were cut and subjected for the 
analysis. Film specimens with physical defects were discarded. The 
films were carefully placed between the two vertical grips of the 
tester during the test. The movable grip was then driven upward 
with a speed of 30mV/min until the rupture of the film. From the 
recorded load extension profiles, the tensile strength, percent 
elongation at break was calculated. 
Folding endurance 
The folding endurance was determined by repeatedly folding one 
film at the same place without breaking [19]. Folding endurance is 
used to estimate the mechanical property of a film [20]. 
Content uniformity 
Content uniformity of films was determined with the assay of ten 
individual films. Each film was transferred to a 20 ml volumetric 
flask and dissolved and extracted in methanol. Drug extracted in 
methanol was analyzed using validated high-performance liquid 
chromatography (HPLC) method [21]. Briefly, drug analysis was 
performed PrincetonSPHER-100 C18 HPLC column (250 mm × 4.6 
mm, 5 μm) with the mobile phase consisting of acetonitrile and 10 
mmolL−1 potassium phosphate buffer adjusted to pH 6.0 with 
triethanolamine (83:17, v/v) at a flow rate of 1 ml/min. Sample 
injection volume was 20 μL and BU detection was performed using 
Shimadzu LC solution software at a wavelength of 284 nm. 
Drug content 
Five films were picked randomly and weighted individually. Each 
film was agitated in methanol and the mixture was suitably diluted 
and analyzed as per developed and validated HPLC method [21]. The 
average drug content was calculated.  
In vitro dissolution 
The in vitro dissolution of the formulations was studied as per the US 
FDA-recommended dissolution methods [22] in 500 ml distilled water 
at 37.0±0.5 °C using the USP Apparatus II (Paddle) at 100 rpm. At 
predetermined time intervals for 30 min, 10 ml of aliquots was 
withdrawn and replaced with an equal volume of fresh distilled water 
to ensure sink condition. Aliquots were then analyzed using developed 
and validated HPLC as described in “Content uniformity.” This in vitro 
dissolution study was performed for optimized formulation F11 and 
F15 (table 1 and 2), developed with proposed strategy of BU 
microemulsion incorporated into sublingual film. The release profile of 
these C2 ME (F11) and A2 ME (F15) sublingual film were compared 
with plain BU sublingual film in which ME was not added.  
Surface pH 
The surface pH of the film formulation was determined by wetting 
the film surface with water and the pH measured using pH probe 
(Contech Instruments Ltd., Navi Mumbai, India) [23]. 
Thickness and weight variation 
The thickness of films was measured using a digital micrometer 
screw gage (Mitutoyo, Microvision Calibration Services, Japan). For 
each formulation, three randomly selected films cut into 20 mm × 
22.5 mm were used. Thickness was measured at five different points 
in the films and mean value was expressed [23]. Each film was 
weighted individually on an analytical balance (Shimadzu, Japan) 
and average weight calculated [24].  
Percent loading of BU ME in sublingual film  
The percent loading of BU ME in sublingual film was determined by 
calculating the amount of ME (g) added to the total casting solution 
of hydrated polymers (g). The film has been casted till no more 
evidence of oiliness was observed on the surface of casting plate 
after removal of dried sublingual strips. The percent loading of BU 
ME in sublingual film was calculated from the following equation:  
Percent loading of BU ME in sublingual �ilm
=
 Amt of BU ME added to casting solution (g)
Total weight of casting solution (g)
100 
Scanning electron microscopy (SEM) 
The morphological characteristics of the films were studied using 
SEM. The purpose of the morphological study was to evaluate the 
film samples for the presence of any deformities, microemulsion 
droplets and cracks. The samples were examined in a Phenom G2 
Pro/G2 pure, Eindhoven, Netherlands, scanning electron microscope 
at an acceleration voltage of 10 kV. 
Ex vivo permeation study 
The ex vivo sublingual permeation of BU through the goat sublingual 
mucosa was performed using a modified Franz glass diffusion cell 
[25]. Goat sublingual mucosa was obtained from the slaughter house 
and mounted between the donor and receptor compartments. The 
developed sublingual film was placed on the smooth surface of 
mucosa by gentle pressing and the compartments were clamped 
together. The donor compartment was moistened with 1 ml of 
distilled water (pH 6.2) and the receptor compartment was filled to 
touch the membrane with distilled water. The fluid motion in the 
receptor compartment was maintained by stirring with a magnetic 
bead at 100 rpm and its temperature was maintained at (37±0.2) °C. 
At predetermined time intervals, a 1 ml sample was withdrawn 
(replaced with fresh medium) and analyzed by developed and 
validated RP-HPLC method [21]. Data analysis was done to calculate 
steady-state fluxes (JSS). 
Droplet size, polydispersity index (PDI) and Zeta potential  
Re-dispersion (o/w microemulsion re-dispersed from films) of 
optimized F27 (BU A2 ME) sublingual film was performed to 
measure particle size and PDI using dynamic light scattering (DLS) 
(Malvern Zetasizer ZEN3500, UK) and zeta potential using the 
nanopartica SZ-100 (Horiba Scientific Ltd., Japan). Rectangular films 
with an area of 4.5 cm2 were placed in 10 ml of de-ionized water. All 
measurements were performed with a scattering angle of 90 ̊ at 
25.0 ̊C after dilute the dispersion to an appropriate volume with 
dispersion medium viscosity 0.894 mPa. s. A small-volume 
disposable zeta cell was used to measure the electrophoretic 
mobility (μm/s) and converted to zeta potential by software using 
the Helmholtz-Smoluchowski equation. 
% Moisture content (Karl Fisher titration method) 
Compact volumetric KF titrator (Metrohm, 915 KF Ti-touch, Swiss 
made) was used for the determination of water content in sublingual 
film. Then film sample of 100.0 mg, was added to glass container 
containing sufficient quantity of KF reagent for complete 
standardization and analysis of sample. Then water content was 
calculated automatically by the apparatus.  
Stability study 
Stability study was performed at room condition and at 40 ̊ C/75% 
RH for 4 w. Each strip of optimized batch F11 and F15 was packed in 
three layered laminated aluminium pouch and ten pouches are 
packed in a carton. After 4 w, the films were evaluated for the 
physical appearance, surface pH and drug content.  
Abuse deterrent potential of developed sublingual film  
An important component of modern pain management includes 
prescription opioid products. However, abuse and misuse of these 
products has created a serious health problem. An important step 
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for creating safer opioid analgesic has been the development of 
opioids that are formulated to deter abuse. These developed 
sublingual films are an abuse deterrent opioid formulation and 
evaluated as per US-FDA guidance to demonstrate that a given 
formulation has abuse deterrent properties [26]. In order to assess 
the impact of a potentially abuse deterrent products, the premarket 
studies are performed that are discussed. 
Laboratory based in vitro manipulation and extraction studies  
The goal of laboratory based extraction studies are to evaluate the 
ease with which the potentially abuse deterrent properties of a 
formulation can be defeated or compromised. The ease with which 
the opioid are extracted from intact and manipulated product should 
be determined using a variety of solvents that are commonly 
available (e. g. water, vinegar, ethanol, iso-propanol, acetone, 
mineral spirits) and those that have potentially relevant solvent 
characteristics (e. g. pH, polarity etc). Accurately weight 145 mg of 
optimized BU A2 ME and NA sublingual film (which contains 4.0 mg 
BU and 1.0 mg NA) was extracted in each 25.0 ml of all above 
mentioned solvents by sonicating for 30 min. 1.0 ml of resulting 
solution was pipetted at time interval of 10 and 30 min in 10.0 ml of 
volumetric flasks and volume made with mobile phase (BU 40 µgml-1 
and NA 10 µgml-1). The resulting solution was filtered using 0.45 µm 
Polytetrafluorethylene (PTFE) filter into standard analytical glass 
vials and analysed using HPLC. Drug extracted in respective solvents 
were analyzed using developed and validated HPLC method [21].  
RESULTS AND DISCUSSION 
Optimization of BU microemulsion loaded and NA sublingual 
film formulation 
In the present study BU microemulsion was incorporated into the 
sublingual film and for that BU C2 ME with Smix ratio of 1:1 and BU A2 
ME with Smix ratio of 2:1 was selected and quantities of each ME was 
fixed as per solubility, to incorporate 2.16 mg dose of BU. Polymers 
with different viscosities such as HPMC E5, E15 and E50 were selected 
and other polymers like xanthan gum and PVA were used for 
development of immediate release sublingual film. These trial batches 
were evaluated for its film forming capacity. Films with xanthan gum 
have poor film forming capacity; whereas film with HPMC polymer has 
good film forming capacity. HPMC E15 grade has good film forming 
capacity as compared to E5. In each of the trial batch the concentration 
of HPMC E15 was increased in order to obtain the complete 
incorporation of microemulsion into the sublingual film. 
For trial batches F5 to F10, oiliness was observed on the surface, 
whereas for optimized lab trial F11, 65.95% of HPMC E15 was 
sufficient to completely incorporate the C2 ME and in F15, 64.92% of 
HPMC E15 was sufficient to completely incorporate A2 ME into the 
sublingual film with no oiliness observed. This exhibited the 
complete % loading of ME in sublingual film. Further scale up trials 
from F16 to F27 were performed on film casting machine by keeping 
drying temperature at 50 ̊ C. Being the sublingual formulation the 
film weight should be minimum for better acceptance. Use of low 
viscosity HPMC E15 resulted into higher film weight, which was not 
acceptable for sublingual administration. HPMC E15 when used in 
quantity below 43.01 mg/film, not sufficient to completely load A2 
ME into the film. In further scale up batches higher viscosity grade 
i.e. HPMC E50 was used and also carbopol 971 P, sodium CMC and 
polyox N80 used in combination. F27 was considered optimized 
scale up batch (fig. 1.), in which HPMC E15 used with HPMC E50 to 
sufficiently reduced the total quantity of polymer required and also 
achieved complete loading of A2 ME into the sublingual film without 
any surface oiliness observed on polyethylene base sheet after 
removal of the sublingual film from the base sheet.  
 
 
Fig. 1: Representative image for optimized buprenorphine and 
naloxone sublingual film (F27) 
 
Characterization of BU microemulsion loaded and NA 
sublingual films 
Physicochemical characteristics of the sublingual film 
The physicochemical properties of the ME loaded sublingual film 
formulations are shown in table 4. Weight variation values (mg) of 
optimized films were in the range of 70.22–71.45 mg. The average 
thickness of all these films ranged from 61.68 to 81.75 µm. Thus 
there was proportional gain in weight of films with that of increase 
in the thickness of films. The optimized sublingual film formulation 
i.e. BU C2 ME sublingual film (F11) and BU A2 ME sublingual film 
(F15) showed the value of folding endurance>20 (table 4). This value 
is desirable because it would not allow easy dislocation of the films 
from the site of application or breaking of film during administration. 
The pH values of optimized films indicate that it will not produce any 
local irritation upon contact with the sublingual mucosa, as it is in the 
range of salivary pH (5.0–7.0) [27]. The slightly acidic pH of the 
formulation was due to the slightly acidic nature of the ME 
incorporated into the sublingual film. This slightly acidic pH of the film 
(F15) helps to deliver the BU in unionized form at the absorption site 
for better bioavailability. Disintegration time of both optimized 
sublingual film formulation was found to disintegrate in less than 30 
sec and has sufficient mechanical strength to bear stress during 
transport and administration of the films. 
 
Table 4: Physiochemical characteristics of the optimized BU Microemulsion loaded and NA sublingual films 
Evaluation parameters F11 (BU C2 ME) F15 (BU A2 ME) 
Thickness (µm) 61.68±1.79 81.75±1.20 
Weight (mg) 70.22±0.24 71.45±0.82 
Folding endurance 21.0±1.0 29.33±1.53 
pH at 25 ̊ C 6.46±0.04 5.87±0.04 
Tensile strength (kg/cm2) 0.305 0.405 
% Elongation at break (%) 2.133 2.066 
Disintegration time (sec) 18.67±1.52 21.33±1.15 
Microemulsion loading (%) 32.56 34.45 
Drug content (%) 101.6±0.35 102.8 ±1.34 
 
In vitro dissolution study 
BU A2 ME sublingual film (F15) showed highest drug release of 96% 
and BU C2 ME sublingual film (F11) showed 62% of drug release 
within 3 min; whereas plain BU sublingual film showed relatively 
less amount of drug release of 23% within 3 min (fig. 2.). This 
exhibited that the proposed strategy of ME incorporated sublingual 
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film reduces the particle size by forming o/w type of ME droplets, 
helps in increasing the surface area and, hence, modulates the drug 
release with a faster rate as compared to the release rate of plain BU 
sublingual film.  
Key attributing factor for differential dissolution profile of F15 and 
F11 are varying concentration of Smix ratio (T-20: PG). This is 
attributed due to higher solubility of BU in co-surfactant i.e. PG and 
its higher concentration was present in F15 formulation i. e Smix ratio 
was 1:1 in F15, whereas less in F11 i.e. 2:1.  
Hence BU A2 ME sublingual film (F15) was considered as an 
optimized formulation based on its in vitro dissolution profile and 
further subjected towards scale up trials and evaluated for SEM 
studies, content uniformity, droplet size, PDI, ZP and ex vivo 
permeation study using goat sublingual mucosa.  
 
 
Fig. 2: In vitro release profile of buprenorphine through BU A2 ME sublingual film (F15), BU C2 ME sublingual film (F11) and plain 
buprenorphine sublingual film 
 
Content uniformity 
The content uniformity of optimized BU A2 ME sublingual film (F27) 
was found to be within the acceptance criteria. The % RSD was 
observed to be less than 2% which indicates uniformity of content. 
Scanning electron microscopy (SEM) 
SEM images of BU A2 ME (F15) and placebo film developed without 
addition of microemulsion was shown in fig. 3 and 4. Well dispersed 
BU microemulsion was obtained in F15, whereas microemulsion 
droplets were not observed in the placebo films developed without 
the addition of microemulsion. SEM images of vaccum oven dried 
microemulsion incorporated film showed spherical shaped 
nanoparticles were embedded in the polymeric matrix.  
 
 
Fig. 3: Scanning electron microphotograph of buprenorphine 
microemulsion loaded and naloxone sublingual film BU A2 ME 
(F15) 
 
Ex vivo permeation study 
Permeation studies through goat sublingual mucosa indicated that 
the % cumulative release of buprenorphine from BU A2 ME 
sublingual film (F15) was 87%, plain BU sublingual film was 30% 
and for naloxone was negligible for nearly 120 min. This indicates 
that the extent of permeation of buprenorphine from F15 was 
around 2.9 folds higher than that of plain buprenorphine sublingual 
film (fig. 5.). Steady state flux (Jss, µgcm/h) were calculated and 
found 37.176 µgcm-2h-1 for F15, 23.056 µgcm-2 h-1 for plain BU 
sublingual film and 5.210 µgcm/h for naloxone sublingual film. This 
evidenced an enhanced permeation of BU when incorporated in 
microemulsion form in sublingual film than over plain 
buprenorphine sublingual film and negligible permeation for 
naloxone across sublingual mucosa. Literature references are also 
available for negligible bioavailability of naloxone via the 
sublingual or oral route [28, 29]. Naloxone an opioid antagonist 
having as such no therapeutic effect but still added to the 
buprenorphine sublingual film formulation in order to only deter 
the intravenous abuse of this formulation, which is mainly done by 
patients for euphoretic effect [30]. 
 
 
Fig. 4: Scanning electron microphotograph of the placebo 
sublingual film without the addition of buprenorphine 
microemulsion 
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Fig. 5: Ex vivo release profile of buprenorphine through BU A2 ME sublingual film (F15), plain buprenorphine sublingual film and plain 
naloxone sublingual film 
 
Droplet size and polydispersity index (PDI) 
Droplet size of optimized F27 (BU A2) microemulsion obtained after 
re-dispersion of sublingual film was 151.5 nm and PDI was 0.445 
which confirmed narrow size distribution of oil droplets (fig. 6.) [31, 
32]. The increased particle size of BU A2 microemulsion after re-
dispersion from sublingual film was may be due to covering of the 
embedded microemulsion with polymeric matrix of sublingual film. 
  
 
Fig. 6: Particle size distribution plot of optimized F27 (BU A2 ME) sublingual film 
 
Zeta potential measurements  
Zeta potential of microemulsion present in optimized BU A2 ME 
sublingual film (F27) obtained after re-dispersion of film was-21.7 
mV. Despite the low ZP value the system remains stable [33]. The 
graph of intensity (a. u.) vs ZP (mV) of A2 ME obtained after re-
dispersion from the sublingual film was exhibited in the fig. 7. 
% Moisture content (Karl Fisher titration method)  
The water content of the optimized F27 (BU A2 ME) sublingual film 
was found to be 7.16 % and its Karl Fischer titration curve graph 
was shown in fig. 8. 
Stability study 
The stability study of �ilm formulations were carried out at room 
condition and at 40 ̊ C/75% RH for a period of one month. The films does 
not show any change in appearance and flexibility. The drug content and 
surface pH was found to be almost constant for upto one month. 
Abuse deterrent potential of developed sublingual film formulation 
Abuse deterrent studies as per US-FDA guidance for industry should 
be conducted in small amount of solvents i.e. 5-10 ml and sampling 
time should start early (e. g. 30 seconds) and continue until at least 
80% of the opioid has been released or if 90% of the opioid can be 
extracted under a set of conditions in 10 min, then there is no need 
to test the same conditions for 30 min [26]. 
BU and NA sublingual film dissolved completely in water, vinegar, 
hydrochloric acid buffer pH 2.0 and phosphate buffer pH 6.0 and pH 
8.0, respectively and resulted into turbid solution after 30 min of 
extraction in all the extraction media (fig. 9. (a, e, g, h) except in 
hydrochloric acid buffer pH 2, clear solution as obtained (fig. 9. (f)). 
However the BU and NA sublingual film during abuse deterrent 
studies remained intact in ethanol, iso-propanol and acetone 
extracting media, whereas a slight jelly type complex was formed in 
ethanol extracting media (fig. 9. (b, c and d)), respectively. 
 
 
Fig. 7: Zeta potential plot of optimized F27 (BU A2 ME) 
sublingual film 
Mundhey et al. 
Int J App Pharm, Vol 12, Issue 6, 2020, 127-135 
133 
 
Fig. 8: Karl fischer titration curve for optimized F27 (BU A2 ME) sublingual film 
 
  
(a)                                   (b) 
 
(c)    (d) 
 
(e)    (f) 
 
(g)   (h) 
Fig. 9: Representative images for laboratory based in vitro manipulation and extraction studies for BU A2 ME and NA sublingual film in (a) 
Water (b) Ethanol (c) Iso-propanol (d) Acetone (e) Vinegar (f) pH 2.0 (g) pH 6.0 (h) pH 8.0 
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Thus abuse deterrent studies passes for BU and NA sublingual film 
in all the extracting media, as about more than 80% of opioid 
antagonist NA was extracted in respective extracting media in 10 
and 30 min of extraction studies as per US-FDA guidance (table 5). 
  
Table 5: Laboratory based in vitro manipulation and extraction studies for BU A2 ME and NA sublingual film in variety of solvents 
S. No. Extracting medium Amount of NA extracted (%) Amount of BU extracted (%) 
10 min 30 min 10 min 30 min 
1 Water 93.1 100.1 73.4 93.3 
2 Ethanol 74.5 89.5 68.1 93.3 
3 Iso-propanol 83.2 98.4 79.9 100.2 
4 Acetone 80.2 94.1 88.4 100.6 
5 Vinegar (5% acetic acid) 85.1 86.8 89.3 98.2 
6 Hydrochloric acid Buffer pH 2.0 56.8 96.9 43.0 93.1 
7 Phosphate Buffer pH 6.0 88.0 104.1 86.8 99.3 
8 Phosphate Buffer pH 8.0 56.4 89.6 43.8 83.5 
 
CONCLUSION 
Two processes namely, preparation of buprenorphine 
microemulsion and their incorporation in sublingual film 
formulation was integrated successfully. SEM studies revealed that 
spherical o/w microemulsion droplets of buprenorphine were 
incorporated in the polymeric matrix of sublingual film. It can be 
revealed from in vitro dissolution and ex vivo permeation studies 
through goat sublingual mucosa that, BU microemulsion-
incorporated sublingual film has enhanced the release rate of drug 
over the plain buprenorphine sublingual film. Further abuse 
deterrent studies revealed that the developed sublingual film was 
abuse deterrent one as 90% of opioid antagonist naloxone was 
extracted from the film within 30 min as per US-FDA guidelines. 
Hence, the present study concludes that abuse deterrent and fast 
acting buprenorphine microemulsion-incorporated sublingual film 
of buprenorphine HCL and naloxone HCL is a promising alternative 
to mostly marketed buprenorphine injectable delivery systems and 
a non-invasive route of administration for breakthrough pain 
management.  
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